Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Purpose: The impact of an increased body mass index (BMI) on outcomes of neoadjuvant chemotherapy (NACT) in breast cancer remains controversial. The purpose of this study was to analyze the impact of BMI on pathological complete response (pCR) rates for operable breast cancer after NACT. Methods: We searched Medline, Embase, and Web of Science database for observational studies and randomized controlled trials that reported the association of BMI with pCR after NACT. We performed a meta-analysis to assess the impact of BMI on pCR rate. Results: We identified 13 studies including a total of 18,702 women with operable breast cancer who underwent NACT. Two studies were pooled analyses of prospective clinical trials (10,669 patients); the rest were case–control studies (8033 patients). All studies provided data of two BMI groups (BMI < 25 vs. BMI ≥ 25). Pooled analyses demonstrated that overweight/obese women were less likely to achieve pCR after NACT as compared to under-/normal weight women (odds ratio (OR) = 0.80; 95% confidence interval (CI): 0.68–0.93). Eleven studies provided data of three BMI groups (BMI < 25, 25 ≤ BMI < 30, BMI ≥ 30). Based on pooled analyses, both overweight and obese groups were less likely to achieve pCR with NACT as compared to under-/normal weight group, (OR = 0.77, 95% CI 0.65–0.93 and OR = 0.68, 95% CI 0.61–0.77, respectively). Conclusions: Overweight and obese breast cancer patients had a lower pCR rate with NACT compared to patients with under-/normal weight. Further prospective studies may help confirm this finding and investigate possible mechanisms.

Original languageEnglish (US)
Pages (from-to)618-629
Number of pages12
JournalBreast Cancer
Volume28
Issue number3
DOIs
StatePublished - May 2021

Bibliographical note

Funding Information:
This study was funded by University of Minnesota Innovation Award.

Funding Information:
The authors would like to express their great appreciation to the Cancer Center Support Grant: NIH/NCI P30 CA 077598, and to professor Naoto Ueno of MD Anderson Cancer Center for his kindness of sharing the dataset with us.

Publisher Copyright:
© 2021, The Japanese Breast Cancer Society.

Keywords

  • Breast cancer
  • Neoadjuvant chemotherapy
  • Obesity
  • Pathological complete response

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis'. Together they form a unique fingerprint.

Cite this